Simvastatin for Treating Erectile Dysfunction (STED)

Santa Casa de Porto Alegre

Status and phase: Completed; Phase 3

Conditions: C Reactive Protein; Erectile Dysfunction; Vascular Disease Detected

Treatments: Drug: Placebo; Drug: Simvastatin

Study type: Interventional

Funder types: Other

Identifiers

NCT00947323

STED

Details and patient eligibility

About

This is a randomized clinical trial, double-blind, placebo controlled, to verify if simvastatin can improve erectile dysfunction in men with endothelial dysfunction, without any cardiac disease.It is hypothesized that the simvastatin can improve the endothelial function, improving the nitric oxide liberation in corpora cavernosa of the penis, resulting in improvement of erection.

Enrollment: 41 patients

Sex: Male

Ages: 35 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Erectile dysfunction
• Elevated C reactive protein
• Able to adhere the protocol

Exclusion criteria

• Diabetes mellitus
• Cardiac disease
• Cerebral vascular disease
• Hypogonadism
• Any contraindication to simvastatin

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: Double Blind

---

41 participants in 2 patient groups, including a placebo group

placebo

Placebo Comparator group

Treatment:

Drug: Placebo

Simvastatin

Experimental group

Description:

Treatment arm.

Treatment:

Drug: Simvastatin